**Supplementary Table 1. Responses to information inquires on the results of interaction after the case investigation using the designed three pairs of HDIs**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Drug Interaction Result (Follow-up) | Community Pharmacy (n=88) | | P value | Hospital Pharmacy (n=168) | | P value | Overall Percentage Mean ± S. D. | |
|  | Others (n=42) | HW(n=46) |  | Others(n=92) | HW(n=76) |  | Others (n=134) | HW (n=122) |
| Angelica - WARFARI N, n(%) |  |  |  |  |  |  |  |  |
| No | 5 (11.9) | 1 (2.2) |  | 2 (2.17) | 2 (2.63) | 0.019 d |  |  |
| Yes | 37 (88.1) | 45 (97.8) |  | 90 (97.83) | 74 (97.37) | 92.96 ± 6.88 | 97.58± 0.82 |
| Ginseng – WARFARIN, n (%) |  |  |  |  |  |  |  |  |
| No | 11 (26.2) | 0 (0) | 0.0002 a | 6 (6.52) | 3 (3.95) | 0.0015 d |  |  |
| Yes | 31 (73.8) | 46 (100) |  | 86 (93.48) | 73 (96.05) | 83.64± 3.80 | 98.02± 0.82 |
| Ginkgo – IBUPROFEN, n (%) |  |  |  |  |  |  |  |  |
| No | 17 (40.5) | 0 (0) | 0.000001 a | 14 (15.22) | 6 (7.89) | 0.001 d |  |  |
| Yes | 25 (59.5) | 46 (100) | 78 (84.78) | 70 (92.11) |  | 72.14 ± 2.35 | 96.05 ± 0.82 |

a: Pearson’s chi square to test differences within community pharmacy group;

d: Pearson’s chi square within the others website users between community and hospital pharmacy groups.

**Supplementary Table 2. Pharmacological mechanism of interaction**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mechanism (Follow-up) | Community Pharmacy (n=88) | | P value | Hospital Pharmacy (n=168) | | P value | Overall Percentage Mean ± S. D. | |
|  | Others (n=42) | HW (n=46) |  | Others (n=92) | HW (n=76) |  | Others (n=134) | HW (n=122) |
| Angelica - WARFARI N, n(%) |  |  |  |  |  |  |  |  |
| No | 12 (28.6) | 6 (13.0) |  | 36 (39.13) | 14 (18.42) | 0.0034 b |  |  |
| Yes | 30 (71.4) | 40 (87.0) |  | 56 (60.87) | 62 (81.58) | 66.14 ± 7.45 | 84.3± 0.82 |
| Ginseng – WARFARIN, n (%) |  |  |  |  |  |  |  |  |
| No | 18 (42.9) | 7 (15.2) | 0.004 a | 37 (40.22) | 10 (13.15) | 0.0001 b |  |  |
| Yes | 24 (57.1) | 39 (84.8) | 55 (59.78) | 66 (86.84) | 58.46 ± 8.22 | 85.8 ± 0.82 |
| Ginkgo – IBUPROFEN, n (%) |  |  |  |  |  |  |  |  |
| No | 25 (59.5) | 8 (17.4) | 0.00004 a | 45 (48.91) | 16 (21.05) | 0.0002 b |  |  |
| Yes | 17 (40.5) | 38 (82.6) | 47 (51.09) | 60 (78.95) | 45.8 ± 14.36 | 80.78 ± 0.82 |

a: Pearson’s chi square to test differences within community pharmacy group;

b: Pearson’s chi square to test differences within hospital pharmacy group;

**Supplementary Table 3. Clinical Management during interaction**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Clinical Management (Follow-up) | Community Pharmacy (n=88) | | P Value | Hospital Pharmacy (n=168) | | P value | Overall Percentage  mean± S. D. | |
|  | Others (n=42) | HW (n=46) |  | Others (n=92) | HW (n=76) |  | Others (n=134) | HW (n=122) |
| Angelica - WARFARI N, n(%) |  |  |  |  |  |  |  |  |
| No | 10 (23.8) | 3 (6.5) | 0.0224 a | 29 (31.52) | 8 (10.53) | 0.001 b |  |  |
| Yes | 32 (76.2) | 43 (93.5) |  | 63 (68.48) | 68 (89.47) | 72.34 ± 5.46 | 91.48 ± 0.82 |
| Ginseng – WARFARIN, n (%) |  |  |  |  |  |  |  |  |
| No | 12 (28.6) | 3 (6.5) | 0.006 a | 23 (25) | 7 (9.21) | 0.0078 b |  |  |
| Yes | 30 (71.4) | 43 (93.5) | 69 (75) | 69 (90.79) | 73.2 ± 0.85 | 92.14 ± 0.82 |
| Ginkgo – IBUPROFEN, n (%) |  |  |  |  |  |  |  |  |
| No | 20 (47.6) | 3 (6.5) | 0.00001 a | 36 (39.13) | 10 (13.16) | 0.0002 b |  |  |
| Yes | 22 (52.4) | 42 (91.3) | 56 (60.87) | 66 (86.84) | 56.64 ± 10.84 | 89.07± 0.82 |
| Not answered | 0 | 1(2.2) |  |  |  |  |  |  |

a: Pearson’s chi square to test differences within community pharmacy group;

b: Pearson’s chi square to test differences within hospital pharmacy group;